NIKKEI 225
36,996.38 -1,083.32 (-2.84%) HANG SENG
16,189.97 -195.90 (-1.20%) CRUDE OIL
85.02 +2.29 (+2.77%) GOLD FUTURES
2,422.30 +24.30 (+1.01%) DOW
37,775.38 +22.07 (+0.06%) Bitcoin GBP
49,465.65 -178.57 (-0.36%)
Ayala Pharmaceuticals, Inc. (ADXS)
| Previous close | 0.6455 |
| Open | 0.5710 |
| Bid | 0.0000 x 3000 |
| Ask | 0.0000 x 1000 |
| Day's range | 0.5000 - 0.5710 |
| 52-week range | 0.5000 - 1.9500 |
| Volume | |
| Avg. volume | 22,879 |
| Market cap | 24.279M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.5100 |
| Earnings date | 21 May 2024 - 27 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireAyala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (Nasdaq: IMNM). As per the terms of the sale, Ayala received from Immunome $20 million in cash and 2,175,489 shares of Immunome common stock, and Immunome assumed specified liabilities related to AL102. Ayala may also receive up to an a
- GlobeNewswire
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. A total of 156 patients were enrolled. ”Completion of enrollment in RINGSIDE represents a significant milestone in the development of AL102,” said Kenneth Berlin, President and Chief Executive Officer of Ayala. “There
- Business Wire
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
BOTHELL, Wash. & MONMOUTH JUNCTION, N.J., February 06, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into a definitive asset purchase agreement with Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, to acquire AL102 and related drug candidate AL101 from Ayala. Based on the terms of the agreement, Immunome will pay Ayala $20 million in cash
